Mutations as Predictive Biomarkers for Adenocarcinoma | Oncohema Key
Diagnosis and Discussion -- Case 1068
![MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/67fdcd54f931874b6e6ffa4ffca44de1124ea7f0/5-Figure1-1.png "MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar")
MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar
Identification of tumor-specific, intronic mutations in Met leading to... | Download Scientific Diagram
MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer Identified by Anchored Multiplex PCR and Next- Generation Sequencing
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer - Journal of Thoracic Oncology
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
Locations of MET exon 14 genomic alterations found in sarcomatoid... | Download Scientific Diagram
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values - Journal of Thoracic Oncology
MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
![PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/df73d74a72129de1592255fc0a74db3d4b45eef3/2-Figure1-1.png "PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar")
PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations - Journal of Thoracic Oncology
Diagnosis and Discussion -- Case 1068
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer - Lung Cancer
Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study Yu Y, Zhang Q, Zhang J, Lu S - J Can Res Ther
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
cMET Exon 14 Skipping: From the Structure to the Clinic - ScienceDirect
Lung cancer with MET exon 14 skipping mutation | LCTT
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
